Zolimetax™ I.V. (Zoledronic acid 4 mg/5 ml ● 4 mg/100 ml)

Zolimetax™ I.V. (Zoledronic acid 4 mg/5 ml ● 4 mg/100 ml)
Product Description

Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone. Treatment of tumour-induced ypercalcaemia.
Brand names/trademarks might be subject to local/regional adaption. Indication for use might differ due to local requirements/registration. Indication(s) given are based on the respective underlying EU marketing authorizations. 

Read more Show less

Pharma Bavaria International GmbH

  • DE
  • 2018
    On CPHI since
  • 1
    Certificates
  • 25 - 49
    Employees
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    Italy
More specifications Fewer specifications
Sales Markets
Show more Show less

Pharma Bavaria International GmbH

  • DE
  • 2018
    On CPHI since
  • 1
    Certificates
  • 25 - 49
    Employees
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Pharma Bavaria International GmbH (2)

  • Parafusiv™ I.V. | Vitopeine™ I.V. (Paracetamol 10 mg/ml; 100 ml ● 50 ml)

    Product Parafusiv™ I.V. | Vitopeine™ I.V. (Paracetamol 10 mg/ml; 100 ml ● 50 ml)

    Vitopeine™ is indicated for the short-term treatment of moderate pain, especially following surgery & treatment of fever, when administration by intravenous routeis clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.
    ...
  • Tafixyl™ I.V. (Tranexamic acid 100 mg/ml; 5 ml ● 10 ml)

    Product Tafixyl™ I.V. (Tranexamic acid 100 mg/ml; 5 ml ● 10 ml)

    Prevention and treatment of bleeding due to local or general fibrinolysis in adults and children 1 year of age and older. Specific indications should be consulted in the SmPC.
    Brand names/trademarks might be subject to local/regional adaption. Indication for use might differ due to local requirem...